Opendata, web and dolomites

ESCALON SIGNED

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ESCALON" data sheet

The following table provides information about the project.

Coordinator
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

Organization address
address: DR MOLEWATERPLEIN 40
city: ROTTERDAM
postcode: 3015 GD
website: www.erasmusmc.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 3˙503˙475 €
 EC max contribution 3˙283˙475 € (94%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2022-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) coordinator 1˙386˙725.00
2    ASOCIACION INSTITUTO BIODONOSTIA ES (DONOSTIA-SAN SEBASTIAN) participant 550˙000.00
3    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 430˙000.00
4    HOSPIAL PRIVADO CENTRO MEDICO DE CORDOBA SA AR (CORDOBA) participant 301˙250.00
5    UNIVERSIDAD SAN FRANCISCO DE QUITO EC (QUITO) participant 172˙750.00
6    MEDIZINISCHE HOCHSCHULE HANNOVER DE (HANNOVER) participant 145˙000.00
7    CENTRO DE ENFERMEDADES HEPATICAS Y DIGESTIVAS SAS CO (BOGOTA) participant 117˙750.00
8    SENSU HOLDING BV NL (GRONINGEN) participant 95˙000.00
9    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 85˙000.00
10    FUNDACAO UNIVERSIDADE FEDERAL DE CIENCIAS DA SAUDE DE PORTO ALEGRE BR (PORTO ALEGRE) participant 0.00
11    THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO CA (TORONTO) participant 0.00

Map

 Project objective

Hepatobiliary malignancies represent a major cause of mortality globally and are uniquely aggressive in Latin America. The most common tumors are: hepatocellular carcinoma (HCC) affecting young individuals in Latin America and being the second most common cause of cancer-related death worldwide; cholangiocarcinoma (CCA) with minimal survival upon diagnosis and largely understudied in the region; gallbladder cancer (GBC) being a rare tumor worldwide but representing the second most common cause of cancer-related death in women in Chile. Key factors related to the excessive mortality of these tumors are the lack of reliable screening methods and the complexity of diagnosis, which requires advanced imaging technology and difficult-to-access tissue. These barriers are amplified by poor accessibility present in resource-limited regions, all of which leads to tumors being diagnosed at advanced stages in which curative therapy is not an option. To overcome these barriers, we propose to: A) validate immune-related markers in serum to predict HCC in South America and evaluate factors associated to early HCC development; B) define the utility of extracellular vesicles in serum as biomarkers for diagnosis of CCA and determine genetic and infectious factors that increase risk for this cancer; and C) identify biomarkers for GBC detection and evaluate novel immune factors that affect the geographical impact of this tumor. This project advances the field by focusing on a unique approach to screen and diagnose tumors based on serum detection of biomarkers before a tumor is visible on imaging, allowing for early tumor detection in a cost effective manner that will lead to implementation of curative therapies. In addition, this project addresses modifiable risk factors for hepatobiliary tumors that could be targeted for prevention. This project will result in novel tools that are easily accessible and will dramatically reduce the burden of cancer-related mortality in Latin America.

 Publications

year authors and title journal last update
List of publications.
2019 Jesus M. Banales, Mercedes Iñarrairaegui, Ander Arbelaiz, Piotr Milkiewicz, Jordi Muntané, Luis Muñoz-Bellvis, Adelaida La Casta, Luis M. Gonzalez, Enara Arretxe, Cristina Alonso, Ibon Martínez-Arranz, Ainhoa Lapitz, Alvaro Santos-Laso, Matias A. Avila, Maria L. Martínez-Chantar, Luis Bujanda, Jose J.G. Marin, Bruno Sangro, Rocio I.R. Macias
Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis
published pages: 547-562, ISSN: 0270-9139, DOI: 10.1002/hep.30319
Hepatology 70/2 2020-04-21
2019 Jose D Debes, Andre Boonstra, Domingo Balderramo, Angelo Z Mattos, Marco Arrese, Juan C. Roa, Juan W. Valle, Jesus M. Banales, Enrique Carrera, Pablo A. Romagnoli, Jhon E. Prieto, Bettina E. Hansen, Arndt Vogel, Angela Lamarca
Hepatobiliary cancers in South America: disparity strikes
published pages: 581, ISSN: 2468-1253, DOI: 10.1016/s2468-1253(19)30188-8
The Lancet Gastroenterology & Hepatology 4/8 2020-04-21

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ESCALON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ESCALON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

RESHAPE (2019)

Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More